Skip to main content
. 2021 Sep 20;8:711203. doi: 10.3389/fcvm.2021.711203

Table 3.

Association of DGX application methods with all-cause death and CVD in RHD patients.

Outcomes Group Before PSM After PSM
Events (N/%) HR (95% CI) P -value Events (N/%) HR (95% CI) P -value
All-cause mortality Unadjusted iDGX 68 (19.5) Ref. 66 (20.6) Ref.
cDGX 151 (39.1) 2.48 (1.87–3.31) <0.001 130 (40.5) 2.49 (1.85–3.34) <0.001
Model 1a iDGX 68 (19.5) Ref. 66 (20.6) Ref.
cDGX 151 (39.1) 1.88 (1.34–2.65) <0.001 130 (40.5) 1.86 (1.31–2.65) 0.001
Model 2b iDGX 68 (19.5) Ref. 66 (20.6) Ref.
cDGX 151 (39.1) 1.73 (1.22–2.59) 0.002 130 (40.5) 1.81 (1.26–2.60) 0.001
Model 3c iDGX 68 (19.5) Ref. 66 (20.6) Ref.
cDGX 151 (39.1) 1.82 (1.28–2.59) 0.001 130 (40.5) 1.84 (1.27–2.65) 0.001
CVD Unadjusted iDGX 32 (9.2) Ref. 31 (9.7) Ref.
cDGX 105 (27.2) 3.65 (2.46–5.42) <0.001 87 (27.1) 3.51 (2.33–5.30) <0.001
Model 1a iDGX 32 (9.2) Ref. 31 (9.7) Ref.
cDGX 105 (27.2) 2.50 (1.54–4.04) <0.001 87 (27.1) 2.46 (1.47–4.12) 0.001
Model 2b iDGX 32 (9.2) Ref. 31 (9.7) Ref.
cDGX 105 (27.2) 2.35 (1.42–3.89) 0.001 87 (27.1) 2.33 (1.36–3.99) 0.002
Model 3c iDGX 32 (9.2) Ref. 31 (9.7) Ref.
cDGX 105 (27.2) 2.24 (1.35–3.73) 0.002 87 (27.1) 2.23 (1.29–3.83) 0.004
a

Model 1: adjusting for baseline adjustment covariates, including age, gender, smoking, drinking, disease duration, NYHA, cardiac valve damage, surgical intervention, medical condition (HT, CHD, T2D, AF at enrolment, and stroke), blood biochemical index (WBC, HGB, PLT, FBG, ALT, AST, Cr, ASO, RF, ESR, BNP, TRIG, TC, LDL-C, HDL-C, serum sodium, and serum potassium), and echocardiography (LAD, LVD, RVD, RAD, and LVEF).

b

Model 2: It was the same as model 1 and also included new-onset AF and combined medication (antiplatelet drugs, warfarin, nitrates, RSIs, BBs, MRAs, CCBs, and statins).

c

Model 3: It was the same as model 2 and also included SDC.

The bold values mean P value <0.05.